148 related articles for article (PubMed ID: 10338505)
1. Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors.
Cirino NM; Sblattero D; Allen D; Peterson SR; Marks JD; Jackson PJ; Bradbury A; Lehnert BE
Infect Immun; 1999 Jun; 67(6):2957-63. PubMed ID: 10338505
[TBL] [Abstract][Full Text] [Related]
2. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation.
Pelat T; Hust M; Laffly E; Condemine F; Bottex C; Vidal D; Lefranc MP; Dübel S; Thullier P
Antimicrob Agents Chemother; 2007 Aug; 51(8):2758-64. PubMed ID: 17517846
[TBL] [Abstract][Full Text] [Related]
3. Selection of human antibodies against cell surface-associated oligomeric anthrax protective antigen.
Steiniger SC; Altobell LJ; Zhou B; Janda KD
Mol Immunol; 2007 Apr; 44(10):2749-55. PubMed ID: 17210180
[TBL] [Abstract][Full Text] [Related]
4. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity.
Maynard JA; Maassen CB; Leppla SH; Brasky K; Patterson JL; Iverson BL; Georgiou G
Nat Biotechnol; 2002 Jun; 20(6):597-601. PubMed ID: 12042864
[TBL] [Abstract][Full Text] [Related]
5. In situ gastrointestinal protection against anthrax edema toxin by single-chain antibody fragment producing lactobacilli.
Andersen KK; Marcotte H; Álvarez B; Boyaka PN; Hammarström L
BMC Biotechnol; 2011 Dec; 11():126. PubMed ID: 22185669
[TBL] [Abstract][Full Text] [Related]
6. Recombinant single-chain variable fragment antibodies directed against Clostridium difficile toxin B produced by use of an optimized phage display system.
Deng XK; Nesbit LA; Morrow KJ
Clin Diagn Lab Immunol; 2003 Jul; 10(4):587-95. PubMed ID: 12853390
[TBL] [Abstract][Full Text] [Related]
7. Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor.
Thullier P; Avril A; Mathieu J; Behrens CK; Pellequer JL; Pelat T
PLoS One; 2013; 8(5):e65855. PubMed ID: 23741517
[TBL] [Abstract][Full Text] [Related]
8. Activity of the Bacillus anthracis 20 kDa protective antigen component.
Hammamieh R; Ribot WJ; Abshire TG; Jett M; Ezzell J
BMC Infect Dis; 2008 Sep; 8():124. PubMed ID: 18808698
[TBL] [Abstract][Full Text] [Related]
9. Role of the Antigen Capture Pathway in the Induction of a Neutralizing Antibody Response to Anthrax Protective Antigen.
Verma A; Ngundi MM; Price GA; Takeda K; Yu J; Burns DL
mBio; 2018 Feb; 9(1):. PubMed ID: 29487236
[TBL] [Abstract][Full Text] [Related]
10. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen.
Chen Z; Moayeri M; Zhou YH; Leppla S; Emerson S; Sebrell A; Yu F; Svitel J; Schuck P; St Claire M; Purcell R
J Infect Dis; 2006 Mar; 193(5):625-33. PubMed ID: 16453257
[TBL] [Abstract][Full Text] [Related]
11. Human monoclonal anti-protective antigen antibody for the low-dose post-exposure prophylaxis and treatment of Anthrax.
Tang Q; Xiong S; Liang X; Kuai X; Wang Y; Wang C; Feng Z; Zhu J
BMC Infect Dis; 2018 Dec; 18(1):640. PubMed ID: 30526504
[TBL] [Abstract][Full Text] [Related]
12. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells.
Escuyer V; Collier RJ
Infect Immun; 1991 Oct; 59(10):3381-6. PubMed ID: 1909998
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of protease-treated Bacillus anthracis protective antigen.
Novak JM; Stein MP; Little SF; Leppla SH; Friedlander AM
J Biol Chem; 1992 Aug; 267(24):17186-93. PubMed ID: 1512256
[TBL] [Abstract][Full Text] [Related]
14. [Screening of full human anthrax lethal factor neutralizing antibody in transgenic mice].
Wang X; Chi X; Liu J; Liu W; Liu S; Qiu S; Wen Z; Fan P; Liu K; Song X; Fu L; Zhang J; Yu C
Sheng Wu Gong Cheng Xue Bao; 2016 Nov; 32(11):1590-1599. PubMed ID: 29034628
[TBL] [Abstract][Full Text] [Related]
15. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.
Albrecht MT; Li H; Williamson ED; LeButt CS; Flick-Smith HC; Quinn CP; Westra H; Galloway D; Mateczun A; Goldman S; Groen H; Baillie LW
Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360
[TBL] [Abstract][Full Text] [Related]
16. Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin.
Zhou B; Carney C; Janda KD
Bioorg Med Chem; 2008 Feb; 16(4):1903-13. PubMed ID: 18023190
[TBL] [Abstract][Full Text] [Related]
17. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694.
Laffly E; Danjou L; Condemine F; Vidal D; Drouet E; Lefranc MP; Bottex C; Thullier P
Antimicrob Agents Chemother; 2005 Aug; 49(8):3414-20. PubMed ID: 16048955
[TBL] [Abstract][Full Text] [Related]
18. Production of Functionally Active and Immunogenic Non-Glycosylated Protective Antigen from Bacillus anthracis in Nicotiana benthamiana by Co-Expression with Peptide-N-Glycosidase F (PNGase F) of Flavobacterium meningosepticum.
Mamedov T; Chichester JA; Jones RM; Ghosh A; Coffin MV; Herschbach K; Prokhnevsky AI; Streatfield SJ; Yusibov V
PLoS One; 2016; 11(4):e0153956. PubMed ID: 27101370
[TBL] [Abstract][Full Text] [Related]
19. Screening and evaluation of human single-chain fragment variable antibody against hepatitis B virus surface antigen.
Zhang JL; Gou JJ; Zhang ZY; Jing YX; Zhang L; Guo R; Yan P; Cheng NL; Niu B; Xie J
Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):237-41. PubMed ID: 16698583
[TBL] [Abstract][Full Text] [Related]
20. The CMG2 ELISA for evaluating inhibitors of the binding of anthrax toxin protective antigen to its receptor.
Dawson RM
J Pharmacol Toxicol Methods; 2009; 59(1):50-5. PubMed ID: 19049885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
